Endothelin antagonism in patients with nondiabetic chronic kidney disease

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Chronic kidney disease (CKD) incidence is rising globally, with cardiovascular disease as a major complication.
• Current CKD treatments managing blood pressure and proteinuria are insufficient for many patients.
• Novel therapies are needed to slow CKD progression and mitigate cardiovascular risks.

Purpose of the Study:

• To explore the role of the endothelin (ET) system in cardiovascular disease and CKD.
• To evaluate the potential of ET antagonists as a therapeutic strategy for CKD patients.
• To investigate the synergistic effects of ET receptor antagonists with ACE inhibitors in managing CKD.

Main Methods:

• Review of existing literature on the ET system's involvement in cardiovascular and renal pathophysiology.
• Analysis of preclinical and clinical data on ET receptor antagonists in CKD models and patient populations.
• Examination of studies investigating combination therapies involving ET antagonists and ACE inhibitors.

Main Results:

• The ET system, particularly ET-1, plays a significant role in hypertension, arterial stiffness, endothelial dysfunction, and atherosclerosis.
• ET antagonism demonstrates potential in improving renal hemodynamics and reducing proteinuria in CKD.
• Emerging data suggest ET receptor antagonists may synergize with ACE inhibitors to slow CKD progression.

Conclusions:

• The ET system is a viable therapeutic target for managing both cardiovascular complications and renal disease progression in CKD.
• ET receptor antagonists offer a promising approach to address unmet needs in CKD treatment.
• Further research into combination therapies may enhance the benefits of ET antagonism in CKD.